• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nanoviricides Inc (NY: NNVC )

    1.470 UNCHANGED
    Streaming Delayed Price Updated: 8:00 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Nanoviricides Inc

    < Previous 1 2 3 4 5 6 Next >
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news affecting shares this morning! 
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
    Via ACCESSWIRE
    A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
    Via ACCESSWIRE
    Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure
    Via ACCESSWIRE
    NanoViricides Has Filed its Quarterly Report
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
    Via AB Newswire
    NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    NNVC Stock Earnings: Nanoviricides Beats EPS for Q3 2024
    NNVC stock results show that Nanoviricides beat analyst estimates for earnings per share the third quarter of 2024. 
    Via InvestorPlace
    A Novel Broad-Spectrum Antiviral with Activity Against RSV
    Via ACCESSWIRE
    A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
    Via ACCESSWIRE
    A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
    Via ACCESSWIRE
    NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire
    Discover three nanotech stocks poised for explosive growth in a booming market. Explore their potential for massive returns. 
    Via InvestorPlace
    NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
    Via ACCESSWIRE
    NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
    Via ACCESSWIRE
    Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
    Via ACCESSWIRE
    A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
    Colds, flu and RSV aren't the only viral illnesses people have to worry about this winter. A new variant of COVID-19 is rapidly spreading, reminding the world of just how dangerous this virus is. 
    Via Benzinga
    Exposures COVID-19
    Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
    Via ACCESSWIRE
    NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024
    NanoViricides, Inc. (NYSE American: NNVC) recently announced that it is presenting at Biotech Showcase™ 2024. Event Information: Event NanoViricides Presentation at the Biotech Showcase, San Fransisco 
    Via Benzinga
    NanoViricides to Present at the Biotech Showcase in San Fransisco
    Via ACCESSWIRE
    Is This Ticker That InvestorsObserver Expects To Soar By More Than 350% Next Year On Your Watchlist?
    --News Direct-- 
    Via News Direct
    Topics Death
    Exposures COVID-19 Death
    The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
    Via ACCESSWIRE
    NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
    Via ACCESSWIRE
    Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
    Via ACCESSWIRE
    NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
    Via ACCESSWIRE
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.